Department of Laboratory, Huantai County People's Hospital, Zibo, 256400, Shandong, China.
Department of General Surgery, Peking University Care Luzhong Hospital, Zibo, 255499, Shandong, China.
Biochem Genet. 2024 Oct;62(5):3761-3773. doi: 10.1007/s10528-023-10618-z. Epub 2024 Jan 13.
Gastric cancer (GC) is one of the crucial causes of cancer-associated death worldwide. This study aimed to investigate the biological function of miR-1286 in GC progression in vitro, evaluate the clinical value of serum miR-1286 to screen GC patients and explore its relationship with helicobacter pylori (HP) infection and peritoneal metastasis in GC patients. Expression of miR-1286 was measured by RT-qPCR. Cell Counting Kit-8 assay was utilized for measuring GC cell proliferation ability. The migration and invasion abilities of GC cells were measured using Transwell assays. Serum samples were obtained from 108 GC patients, 62 gastritis cases and 62 healthy volunteers. The diagnostic performance of miR-1286 was assessed using ROC analysis, and the predictive value of miR-1286 for peritoneal metastasis onset was analyzed using logistic regression analysis. miR-1286 played as a tumor suppressor in GC progression by inhibiting GC cell proliferation, migration and invasion. In GC patients, significantly decreased miR-1286 was observed compared to gastritis and healthy controls, and had considerable diagnostic accuracy to distinguish GC from the controls. A significant association was found between miR-1286 expression and HP infection, peritoneal metastasis and TNM stage. Moreover, miR-1286 was lowly expressed in GC patients with peritoneal metastasis, and independently predicted the occurrence of peritoneal metastasis in GC. miR-1286 acts as a tumor suppressor and a biomarker in GC, and is closely associated with HP infection and peritoneal metastasis onset. The methods to regulate miR-1286 may be novel strategies to improve the treatment of GC.
胃癌（GC）是全球癌症相关死亡的重要原因之一。本研究旨在探讨 miR-1286 在体外 GC 进展中的生物学功能，评估血清 miR-1286 筛查 GC 患者的临床价值，并探讨其与 GC 患者中幽门螺杆菌（HP）感染和腹膜转移的关系。通过 RT-qPCR 测定 miR-1286 的表达。使用细胞计数试剂盒-8 测定 GC 细胞增殖能力。使用 Transwell 测定 GC 细胞的迁移和侵袭能力。从 108 例 GC 患者、62 例胃炎患者和 62 例健康志愿者中获得血清样本。通过 ROC 分析评估 miR-1286 的诊断性能，并通过逻辑回归分析分析 miR-1286 对腹膜转移发生的预测价值。miR-1286 通过抑制 GC 细胞增殖、迁移和侵袭在 GC 进展中起肿瘤抑制作用。与胃炎和健康对照组相比，GC 患者的 miR-1286 表达明显降低，对 GC 与对照组的鉴别具有相当的诊断准确性。miR-1286 的表达与 HP 感染、腹膜转移和 TNM 分期之间存在显著相关性。此外，miR-1286 在有腹膜转移的 GC 患者中表达较低，并且独立预测 GC 患者腹膜转移的发生。miR-1286 在 GC 中作为肿瘤抑制因子和生物标志物发挥作用，与 HP 感染和腹膜转移的发生密切相关。调节 miR-1286 的方法可能是改善 GC 治疗的新策略。
